10 completed, 4 unknown, 3 recruiting, 1 active not recruiting. 8 Phase 2, 3 Phase 3, 2 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 2, Terminated 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Not applicable | 2 | Active not recruiting 1, Unknown 1 |
| Phase 4 | 1 | Unknown 1 |
Follow The Parkinson Study Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) Adalimumab, Placebo - REM Sleep Behavior Disorder | Phase 2 | Recruiting | Yale University | 108 | 2026-08-17 | 2026-10-08 |
| Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease HBI-002, Vehicle (placebo) - Parkinson Disease | Phase 2 | Recruiting | Hillhurst Biopharmaceuticals, Inc. | 36 | 2026-06-30 | 2026-09-21 |
| Study in Parkinson Disease of Exercise Treadmill walking - Parkinson Disease | Not applicable | Active not recruiting | Northwestern University | 370 | 2021-08-30 | 2026-07-10 |
| Auricular Muscle Zone Stimulation for Parkinson Disease Earstim - Active Stimulation, Earstim - Sham Stimulation - Parkinson Disease | Phase 2 | Completed | Stoparkinson Healthcare Systems LLC | 38 | 2021-05-01 | 2022-01-11 |
| A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease UCB0599, Placebo - Early-stage Parkinson's Disease | Phase 2 | Completed | UCB Biopharma SRL | 496 | 2020-12-30 | 2025-10-31 |
| Parkinson's Foundation PD GENEration Genetic Registry Lab Assay for seven genetic variants for Parkinson's Disease - Parkinson's Disease | Recruiting | Parkinson's Foundation | 35382 | 2020-12-20 | 2026-09-08 | |
| PDGeneration: Mapping the Future of Parkinson's Disease Lab Assay for seven genetic variants for Parkinson's Disease - Parkinson's Disease and Parkinsonism | Not applicable | Unknown | Parkinson's Foundation | 1982 | 2019-08-15 | 2023-07-14 |
| Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials Parkinson Disease | Completed | Massachusetts General Hospital | 226 | 2018-10-01 | 2023-06-12 | |
| Validation of a Non-Motor Fluctuation Assessment Instrument (NoMoFA) for Parkinson's Disease Parkinson Disease | Completed | Assistive Technology Clinic, Canada | 202 | 2018-09-13 | 2020-07-08 | |
| Study of Urate Elevation in Parkinson's Disease, Phase 3 Inosine, Placebo - Parkinson's Disease | Phase 3 | Completed | Michael Alan Schwarzschild | 298 | 2016-06-01 | 2020-07-28 |
| Efficacy of Isradipine in Early Parkinson Disease Isradipine, Placebo (for Isradipine) - Parkinson Disease | Phase 3 | Completed | University of Rochester | 336 | 2014-11-01 | 2020-01-14 |
| Nicotine Treatment of Impulsivity in Parkinson's Disease nicotine patch, placebo - Parkinson's Disease | Phase 4 | Unknown | University of Vermont | 20 | 2010-10-01 | 2013-05-14 |
| Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease Isradipine CR 5mg, Isradipine CR 10mg, Isradipine CR 20mg - Parkinson Disease | Phase 2 | Completed | Northwestern University | 99 | 2009-07-01 | 2013-04-17 |
| Safety of Urate Elevation in Parkinson's Disease Placebo, inosine - Parkinson Disease | Phase 2 | Completed | The Parkinson Study Group | 75 | 2009-06-01 | 2014-06-05 |
| Diagnostic and Prognostic Biomarkers in Parkinson Disease Parkinson Disease, Multiple System Atrophy | Unknown | The Parkinson Study Group | 200 | 2007-08-01 | 2008-12-31 | |
| A Longitudinal Observational Follow-up of the PRECEPT Study Cohort Parkinson Disease | Unknown | The Parkinson Study Group | 530 | 2006-08-01 | 2008-03-28 | |
| POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease Premarin ® - Parkinson's Disease | Phase 2 | Completed | The Parkinson Study Group | 23 | 2003-10-01 | 2008-01-08 |
| Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg - Parkinson Disease | Phase 2 / Phase 3 | Terminated | Cephalon | 806 | 2002-03-01 | 2012-05-10 |
| Parkinson's Research: The Organized Genetics Initiative Parkinson Disease | Completed | Indiana University | 1800 | 1998-08-01 | 2011-02-16 |
Parkinson Disease (18) · Disease Progression (1) · Multiple System Atrophy (1) · Parkinsonian Disorders (1) · REM Sleep Behavior Disorder (1) · Supranuclear Palsy, Progressive (1) · Synucleinopathies (1)
Inosine (2) · Isradipine (2) · 3,9-bis((ethylthio)methyl)-K-252a (1) · Adalimumab (1) · Estrogens, Conjugated (USP) (1) · Tobacco Use Cessation Devices (1)
United States (18) · Canada (10) · Puerto Rico (3) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1)
Michael A Schwarzschild, MD, PhD (3) · Tanya Simuni, MD (2) · Alberto Ascherio, MD, DrPH (1) · Bernard Ravina, MD (1) · Daniel M Corcos, PhD (1) · David Oakes, PhD (1) · E. Ray Dorsey, MD, MBA (1) · Eric A Macklin, PhD (1) · Galit Kleiner, MD (1) · James Beck, PhD (1) · James Boyd, MD (1) · Jesse Cedarbaum, MD (1) · Larsson Omberg, PhD (1) · Lisa M Shulman, MD (1) · Robert Holloway, MD MPH (1)
PMID 36865634, PMID 17881719, PMID 18413464, PMID 24366103, PMID 28958801, PMID 30741695, PMID 31484712, PMID 32227247, PMID 33460320, PMID 33942376, PMID 34519802, PMID 36203214, PMID 37460603
U01NS050095 (2), U01NS080818 (2), U01NS080840 (2), U01NS090259 (2), R01AG095016 (1), R01NS037167 (1)